Detailed price information for Exact Sciences Cor (EXAS-Q) from The Globe and Mail including charting and trades.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes ...

Arcus Biosciences (NYSE:RCUS), Inc., a biotechnology company focused on developing innovative cancer therapies, has been garnering attention from investors and analysts alike. The company’s ...

Arcus Biosciences, Inc. (NASDAQ:NYSE:RCUS), a biopharmaceutical company focused on developing innovative cancer therapies, stands at a critical juncture in its journey to bring novel treatments to ...

HAYWARD, Calif., May 27, 2025--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and ...

On Tuesday, H.C. Wainwright analysts reiterated a Buy rating for Arcus Biosciences stock (NYSE: NYSE:RCUS) and maintained a price target of $24.00, significantly above the current trading price of ...

Last month Arcus reported top -line phase 2 results with the TIGIT drug that it said warranted taking it forward into a phase 3 programme, but so far there's no word from Gilead on a buy-in.

Business Central CEO Simon Arcus told Ryan Bridge things will probably still fluctuate in coming years. He says there are often moments where things seem to improve, then sink back again.

Spider-Man '94 is a four-issue limited series that picks up where the show's infamous cliffhanger ending left off in 1998. The series brings Peter Parker and Mary Jane Watson back to New York and ...